Intermittent Pneumatic Compression + Exercise for Peripheral Arterial Disease
(INTERCEDE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The INTERCEDE randomized trial will establish whether six-months of intermittent pneumatic compression combined with walking exercise improves walking endurance at six-month follow-up, compared to walking exercise + sham compression therapy, in people with lower extremity peripheral artery disease (PAD). The INTERCEDE trial will also determine whether intermittent pneumatic compression therapy improves walking endurance at 6-month follow-up, compared to a sham compression therapy. The trial will also determine whether benefits of intermittent pneumatic compression persist after intermittent pneumatic compression treatment is completed.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you started taking cilostazol within the last three months, you may need to wait until three months have passed to be eligible.
Is the combination of exercise and intermittent pneumatic compression safe for humans?
How does the treatment of Intermittent Pneumatic Compression + Exercise for Peripheral Arterial Disease differ from other treatments?
This treatment is unique because it combines exercise with intermittent pneumatic compression (IPC), which uses a device to apply pressure to the legs, improving blood flow and oxygenation. Unlike other treatments, IPC mimics the natural pumping action of walking, potentially enhancing circulation and reducing symptoms like claudication (pain caused by too little blood flow).678910
What data supports the effectiveness of this treatment for Peripheral Arterial Disease?
Who Is on the Research Team?
Mary McDermott, MD
Principal Investigator
Northwestern Universtiy
Are You a Good Fit for This Trial?
This trial is for individuals with Peripheral Artery Disease (PAD), confirmed by an ankle-brachial index (ABI) of ≤0.90, or other vascular/angiographic evidence. Exclusions include wheelchair users, BMI >45 kg/m2, significant visual impairment affecting walking, non-English speakers, recent amputees or clinical trial participants, certain cognitive impairments and severe medical conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intermittent pneumatic compression and/or sham therapy, with or without exercise, for six months
Follow-up
Participants are monitored for changes in walking endurance and other health metrics after treatment
Long-term Follow-up
Participants are assessed for the persistence of treatment benefits and additional health outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Exercise
- Intermittent Pneumatic Compression
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor
National Institute on Aging (NIA)
Collaborator